Product Pipeline
- Tuxarin ER
- SPSO 1002
- SPSO 1003

Tuxarin ER®
“First Long Acting Tablet, Schedule III, Codeine Antitussive Combination with Chlorpheniramine Antihistamine”

- Long acting
- DEA Schedule III
- 40 mg codeine/chlorpheniramine combo tablet
- Minimize serious risk of over dosing
- No splits or taste issues
- Patent Protected-OB listable issued claims

TUXARIN ER presentation

- Vast majority of patients with cough, cold & flu also have runny nose symptoms.
- Currently most codeine containing antitussives require four to six (4-6) times a day dosing.
- Chlorpheniramine is an antihistamine that blocks histamine receptors. Histamine is a chemical that causes inflammation and sneezing. It helps to dry your runny nose, provide relief for sneezing, itchy and watery eyes, and itching of the nose, throat, and roof of the mouth, and calm the cough.
- Chlorpheniramine is most widely used antihistamine to manage cough and cold symptoms.
- Issues with Hydrocodone and Chlorpheniramine commercial products
  - Current market is dominated by liquids prone to serious risk of dosing errors.
- Issues with Promethazine (antihistamine) plus Codeine commercial products
  - Current market is dominated by short acting liquids that are prone to dosing errors.
  - FDA requires boxed warning added to all promethazine containing products
  - Unlike promethazine no known serious safety issues with Chlorpheniramine